https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-24 / J. Clin. Invest. 2013 Jul;123(7):3135-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-24 / J. Clin. Invest. 2013 Jul;123(7):3135-452013-06-24 00:00:002019-02-15 08:48:46Melanoma immunotherapy using mature DCs expressing the constitutive proteasome
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-04 / J Clin Oncol 31, 2013 (suppl; abstr e20042)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-04 / J Clin Oncol 31, 2013 (suppl; abstr e20042)2013-06-04 11:44:592019-07-17 11:45:20Biochemical and immunologic markers in patients with metastatic melanoma treated with chemotherapy and dendritic cell vaccine.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3040)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3040)2013-06-03 11:37:322019-07-17 11:38:06Effect of vaccination with autologous tumor-loaded dendritic cells on intratumoral regulatory T cells in metastatic melanoma patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-15 / Cancer Immunol. Immunother. 2013 Apr;62(4):761-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-15 / Cancer Immunol. Immunother. 2013 Apr;62(4):761-722012-12-15 00:00:002019-02-15 08:49:50The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-07 / Oncol. Rep. 2012 Oct;28(4):1131-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-07 / Oncol. Rep. 2012 Oct;28(4):1131-82012-08-07 00:00:002019-02-15 08:48:47Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr e13059)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr e13059)2012-06-04 11:46:052019-07-17 11:46:27Autologous dendritic cell vaccine (ADCV) in combination with plasmapheresis (PP) and cyclophosphamide (Cy) in patients with disseminated melanoma: A phase II study.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2525)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2525)2012-06-02 11:40:292019-07-17 11:40:54CD40 ligand/interferon-γ matured DC immunization with gp100 antigen HLA class I A *0201 restricted peptides in patients with newly diagnosed metastatic melanoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2524)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2524)2012-06-02 11:39:352019-07-17 11:39:58Adjuvant dendritic cell (DC)-based vaccine therapy of melanoma patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-20 / Cancer Immunol. Immunother. 2012 Oct;61(10):1791-804
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-20 / Cancer Immunol. Immunother. 2012 Oct;61(10):1791-8042012-03-20 00:00:002019-02-15 08:48:48Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Curr. Top. Microbiol. Immunol. 2012;351:181-220
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Curr. Top. Microbiol. Immunol. 2012;351:181-2202012-01-01 00:00:002019-02-15 08:49:17The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma
